Vincent Khor

Dr. Vincent Khor is a young urologist with a sub-specialty interest in uro-oncology, focused on prostate cancer diagnostics, robotic surgery, and focal therapy. He completed his MBBS at Manipal University in 2013, MRCS (Ireland) in 2015, and Master of Surgery (ChM) in Urology from the University of Edinburgh in 2019. He completed his urology training in Malaysia in 2024 and obtained the FRCS (Urol) from Glasgow. Dr. Vincent is an alumnus of Harvard Medical School’s Global Clinical Scholar Research Training program and the first Malaysian to receive a clinical visit scholarship from the European Association of Urology. He has played a key role in establishing MRI-US fusion biopsy and focal therapy services for localized prostate cancer at the Universiti Putra Malaysia Teaching Hospital. He was awarded the Ten Outstanding Penang Youth 2024 Award for his contributions to medicine and the community.

15th August 2025

Time	Session

13:30 15:00	Industry Symposium 3 【Sonablate】 Advancing Focal Therapy in Localized Prostate Cancer: From Patient Stratification to Post-HIFU Management Introduction and Welcome Po-Hui Chiang Taiwan Speaker Shoji SunaoJapan Speaker Update of Localized Prostate Cancer Therapy Yi-Hsiu HuangTaiwan Moderator Jen-Chieh ChenTaiwan Speaker Who is NOT the patient for Focal Therapy? Kae Jack Tay Singapore Moderator Vincent KhorMalaysia Speaker Oncological and Functional Outcomes of Focal Therapy Kuan-Chou ChenTaiwan Moderator Peter Ka-Fung ChiuHong Kong, China Speaker Minimal Invasive Therapy: Where do We Stand in 2025Endourological, Laparoscopic and robotic surgeries have replaced most open surgeries in Urology. Emergence of new robotic platforms have provided urologists with new opportunities. Both boom-type and module-type robots have been used, and they each have their strengths in practice. Tele-surgeries have provided a new paradigm of long-distance robotic surgeries to facilitate new surgical possibilities and proctorship. State of the art robotic surgeries in retrograde intrarenal surgeries and enbloc resection MDT Discussion: Personalizing Treatment in High Volume CSPCN/ADebate: Should We Only Offer Consolidative Cytoreductive Nephrectomy in Metastatic RCC?N/AFocal Therapy in Asia – Is It Prime Time?The increase in incidence of Prostate cancer has been rapid in Asia in the past 10 years. While Robotic radical prostatectomy and Radiotherapy has been the commonest treatments for localized prostate cancer, significant long-term morbidities are observed after surgery or radiotherapy including incontinence, erectile dysfunction and irradiation injury to the bladder and rectum. In the current era of MRI-guided prostate biopsy, focal diseases can be targeted and diagnosed, and image-guided focal therapy emerged as an alternative treatment. Although Focal therapy has a relatively higher rate of local recurrence, it has the advantages of minimal or no long-term complication after treatment, and it is possible to perform retreatment with focal therapy, prostatectomy or radiotherapy. In properly selected patients, the need for salvage prostatectomy or radiotherapy after focal therapy is less than 20% at 8 years, and patients’ quality of life could be preserved. In well-selected patients, focal therapy is an attractive option. Current focal therapy for prostate cancer available in Asia includes HIFU, Cryotherapy, Targeted Microwave Ablation (TMA), irreversible electroporation (IRE) and TULSA. Beyond Oncologic Control: Real-World Experience in Patient-Centered HIFU for Prostate Disease Shin-Hong ChenTaiwan Moderator L Sivaneswaran LechmiannandanMalaysia Speaker Follow-Up after HIFU Treatment Yu ChenTaiwan Moderator Po-Fan HsiehTaiwan Speaker Panel Discussion Mark EmbertonUnited Kingdom Moderator Shoji SunaoJapan Moderator Jacob See-Tong PangTaiwan Moderator Po-Hui Chiang Taiwan Moderator Closing Jacob See-Tong PangTaiwan Speaker TICC - 1F 101B

Time

Session

13:30

15:00

Industry Symposium 3 【Sonablate】

Advancing Focal Therapy in Localized Prostate Cancer: From Patient Stratification to Post-HIFU Management

Introduction and Welcome

Po-Hui Chiang Taiwan Speaker

Shoji SunaoJapan Speaker
Update of Localized Prostate Cancer Therapy

Yi-Hsiu HuangTaiwan Moderator

Jen-Chieh ChenTaiwan Speaker
Who is NOT the patient for Focal Therapy?

Kae Jack Tay Singapore Moderator

Vincent KhorMalaysia Speaker
Oncological and Functional Outcomes of Focal Therapy

Kuan-Chou ChenTaiwan Moderator

Peter Ka-Fung ChiuHong Kong, China Speaker Minimal Invasive Therapy: Where do We Stand in 2025Endourological, Laparoscopic and robotic surgeries have replaced most open surgeries in Urology. Emergence of new robotic platforms have provided urologists with new opportunities. Both boom-type and module-type robots have been used, and they each have their strengths in practice. Tele-surgeries have provided a new paradigm of long-distance robotic surgeries to facilitate new surgical possibilities and proctorship. State of the art robotic surgeries in retrograde intrarenal surgeries and enbloc resection MDT Discussion: Personalizing Treatment in High Volume CSPCN/ADebate: Should We Only Offer Consolidative Cytoreductive Nephrectomy in Metastatic RCC?N/AFocal Therapy in Asia – Is It Prime Time?The increase in incidence of Prostate cancer has been rapid in Asia in the past 10 years. While Robotic radical prostatectomy and Radiotherapy has been the commonest treatments for localized prostate cancer, significant long-term morbidities are observed after surgery or radiotherapy including incontinence, erectile dysfunction and irradiation injury to the bladder and rectum. In the current era of MRI-guided prostate biopsy, focal diseases can be targeted and diagnosed, and image-guided focal therapy emerged as an alternative treatment. Although Focal therapy has a relatively higher rate of local recurrence, it has the advantages of minimal or no long-term complication after treatment, and it is possible to perform retreatment with focal therapy, prostatectomy or radiotherapy. In properly selected patients, the need for salvage prostatectomy or radiotherapy after focal therapy is less than 20% at 8 years, and patients’ quality of life could be preserved. In well-selected patients, focal therapy is an attractive option. Current focal therapy for prostate cancer available in Asia includes HIFU, Cryotherapy, Targeted Microwave Ablation (TMA), irreversible electroporation (IRE) and TULSA.
Beyond Oncologic Control: Real-World Experience in Patient-Centered HIFU for Prostate Disease

Shin-Hong ChenTaiwan Moderator

L Sivaneswaran LechmiannandanMalaysia Speaker
Follow-Up after HIFU Treatment

Yu ChenTaiwan Moderator

Po-Fan HsiehTaiwan Speaker
Panel Discussion

Mark EmbertonUnited Kingdom Moderator

Shoji SunaoJapan Moderator

Jacob See-Tong PangTaiwan Moderator

Po-Hui Chiang Taiwan Moderator
Closing

Jacob See-Tong PangTaiwan Speaker

TICC - 1F 101B